Complix to Present at Upcoming BioEquity Europe 2013
HASSELT, Belgium, May 21, 2013 /PRNewswire/ –
Complix, a biopharmaceutical company focused on the discovery and development of
Alphabodies(TM), a unique class of protein therapeutics that are active against
intracellular disease targets, announces that its CEO Dr Mark Vaeck will present at
BioEquity Europe 2013 in Stockholm, Sweden (May 22nd-23rd). Details of the presentation
are listed below.
Dr Vaeck will highlight Complix’ recent progress in applying its revolutionary
Alphabody(TM) platform to generate novel therapeutics with first-in-class potential.
Alphabodies represent a transformative therapeutic development platform with the
capacity to address a vast number of disease targets that are currently considered
“undruggable” by the two main classes of therapeutic drugs: small chemical drugs and
therapeutic antibodies. In particular, their ability to act on intracellular protein
targets represents a major medical and commercial opportunity.
Complix has been developing Cell-Penetrating Alphabodies (CPABs), which have the
unique capacity to enter cells effectively and modulate intracellular protein-to-protein
interactions (PPIs). Most recently the Company’s research team has generated compelling
data showing that CPABs, specific for an intracellular cancer target, are able to
specifically interact with this target and cause significant biological effects on the
cancer cells, in vitro as well as in vivo.
Dr Mark Vaeck, CEO of Complix, comments: “Our recently generated data on Alphabodies,
particularly CPABs, show the promise of our Alphabody platform to transform drug
development as we know it today. Alphabodies represent a unique therapeutic class. Unlike
currently available biologics or small molecule drugs, Alphabodies have the potential to
target a broad and validated but untouched target universe of proteins that are located
inside cells. The unprecedented versatility, stability and cell penetrating capacity of
Alphabodies enables them to target these intracellular PPIs, which are known to play a key
role in the initiation and progression of major diseases such as cancer, autoimmunity, CNS
and metabolic diseases. We are confident that our Alphabody platform can create
next-generation therapeutics that will make a real difference in the treatment of disease
and ultimately to the life of patients.”
Details of the presentation are as follows:
Title: Complix NV Time: Wednesday May 22nd, 2013 at 3.30-3.55pm CET Location: Drottingholmsalen A Venue: Sheraton Stockholm Hotel
Complix is a biopharmaceutical company developing a pipeline of transformative protein
therapeutics, called Alphabodies(TM), mainly focused on oncology and
autoimmunity/inflammation. Alphabodies are a revolutionary class of protein therapeutics
that combine attractive features from antibodies, like high target specificity and
affinity, with benefits from small chemicals like extreme stability and cell penetration
capacity. Alphabodies are small, single-chain proteins, with a triple-stranded
alpha-helical coil structure, designed by computer modeling, but inspired by naturally
existing protein motifs. Thanks to their unique features, Alphabodies can address a wide
range of disease targets, both intracellular and extracellular, that are considered
undruggable by conventional small chemicals or biologics.
Complix has established a strong intellectual property position protecting the
Alphabody(TM) platform and its emerging product portfolio through the filing of multiple
broad patent applications. Alphabody-based therapeutics are independent of antibody-based
patent claims and offer a unique freedom-to-operate position.
The Company has raised close to EUR14 million in funding (approximately US$18
million), including a EUR7 million Series A equity round in 2010 with Vesalius Biocapital,
LRM and Omnes Capital as main investors.
Complix is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille,
and has research facilities in Ghent (Belgium) and in Luxembourg. The Company has a fully
owned subsidiary in Luxembourg and has established research alliances with CRP-Sante
(Luxembourg) and VIB (Belgium). For further information, please visit
Complix NV Dr. Mark Vaeck, CEO +32-9-261-69-40